surviv
member
outbreak
jordan
expos
contact
household
member
identifi
serolog
either
merscov
posit
indetermin
ask
consent
particip
particip
ask
provid
followup
serolog
specimen
could
compar
result
result
specimen
prepar
jordan
central
public
health
laboratori
amman
jordan
test
us
center
diseas
control
prevent
atlanta
ga
usa
antibodi
titer
serum
sampl
determin
nucleocapsid
indirect
elisa
merscov
strain
indirect
ifa
presenc
neutral
antibodi
titer
determin
microneutr
live
merscov
strain
biosafeti
level
laboratori
describ
previous
neutral
titer
defin
reciproc
highest
serum
dilut
complet
protect
vero
cell
monolay
cytopath
effect
least
parallel
well
titer
report
posit
surviv
person
posit
serolog
test
result
consent
followup
test
surviv
person
posit
serolog
test
result
month
merscov
outbreak
also
consent
person
consid
probabl
merscov
casepati
accord
world
health
organ
criteria
symptomat
acut
respiratori
infect
outbreak
period
document
unprotect
exposur
person
case
confirm
revers
transcript
pcr
probabl
casepati
elisa
titer
month
rang
repres
reduc
antibodi
titer
compar
estim
person
tabl
nurs
work
intens
care
unit
particip
care
confirm
casepati
outbreak
particip
elisa
indic
consist
titer
time
particip
neutral
antibodi
titer
rang
followup
evalu
decreas
neutral
antibodi
titer
time
one
particip
detect
neutral
antibodi
figur
particip
ifa
result
posit
month
posit
result
month
surviv
particip
whose
serolog
result
month
indetermin
consent
test
report
respiratori
symptom
report
mild
respiratori
symptom
hospit
respiratori
infect
document
unprotect
exposur
casepati
person
neg
serolog
test
result
month
continu
consid
neg
overal
antibodi
merscov
includ
neutral
antibodi
persist
person
month
merscov
outbreak
jordan
observ
persist
antibodi
contribut
understand
individu
immun
respons
merscov
infect
populationbas
immun
region
merscov
outbreak
occur
effort
develop
effect
vaccin
therapeut
counter
merscov
infect
notwithstand
improv
public
health
awar
infect
control
practic
affect
countri
arabian
peninsula
middl
east
emerg
viru
eg
introduct
south
korea
result
epidem
ongo
merscov
continu
pose
grave
risk
intern
healthcar
socioeconom
system
hypothes
mild
asymptomat
merscov
infect
potenti
associ
lower
level
merscov
neutral
antibodi
time
casepati
report
respiratori
symptom
rel
young
underli
medic
condit
tabl
associ
merscov
antibodi
result
clinic
sever
therefor
difficult
assess
nonetheless
person
chest
radiograph
show
substanti
chang
within
day
symptom
onset
remain
posit
microneutr
month
outbreak
although
similar
shortterm
develop
antibodi
merscov
sarscov
eg
seroconvers
week
ill
onset
observ
longer
term
serum
antibodi
kinet
infect
yet
compar
sarscov
infect
robust
igg
titer
observ
second
year
declin
substanti
third
year
infect
find
gener
reduc
persist
merscov
antibodi
respons
even
month
suggest
potenti
longer
last
antibodymedi
protect
immun
reinfect
howev
whether
longlast
antibodi
prevent
reinfect
affect
clinic
outcom
yet
examin
divers
individu
antibodi
test
result
allud
potenti
role
genet
factor
explain
observ
differ
immunolog
respons
merscov
exposur
infect
time
merscov
antibodi
measur
studi
chosen
logist
field
practic
although
limit
outbreak
merscov
occur
jordan
sinc
contact
trace
effort
investig
jordan
lead
us
believ
person
subsequ
expos
observ
elisa
titer
neutral
antibodi
titer
support
supposit
otherwis
would
expect
increas
result
booster
effect
secondari
exposur
infect
assess
durat
resili
merscov
antibodi
human
popul
continu
followup
serolog
evalu
person
would
desir
